SLC6A6介导的牛磺酸摄取维持角膜上皮干/祖细胞功能以对抗年龄相关功能障碍
该研究探讨SLC6A6介导的牛磺酸转运在维持角膜缘干/祖细胞(LSPC)功能中的作用及其对年龄相关角膜伤口愈合的意义。小鼠角膜表达高水平牛磺酸,其转运体SLC6A6主要定位于LSPC且呈年龄依赖模式;抑制SLC6A6延迟角膜伤口愈合、激活衰老通路并下调干细胞标志物,局部补充牛磺酸可逆转该功能衰退。
要点
- 角膜富含牛磺酸,其转运体SLC6A6主要表达于角膜缘干/祖细胞且随年龄变化。
- 抑制SLC6A6可延迟角膜伤口愈合、激活衰老通路并下调干细胞与增殖标志物。
- 局部补充牛磺酸可逆转SLC6A6抑制导致的功能衰退,Notch1信号通路参与其中。
核心结论
- SLC6A6驱动的牛磺酸摄取关键调控LSPC稳态,为年龄相关角膜疾病提供治疗策略。
研究设计与样本
- 研究采用C57BL/6J小鼠角膜氨基酸谱分析、单细胞RNA测序、定量PCR和免疫荧光。
- 通过胍基乙基磺酸(GES)药理学抑制SLC6A6,并在角膜伤口愈合模型及小鼠角膜上皮干/祖细胞(TKE2)细胞中进行转录组和功能分析。
- 老年小鼠刮除角膜上皮后接受局部牛磺酸补充(25 mg/mL,每日5次),收集角膜进行免疫荧光染色。
- TKE2细胞分别接受GES联合Notch1激动剂丙戊酸(VPA)处理,或牛磺酸联合Notch1抑制剂GSI-IX(DAPT)处理。
主要发现
- 角膜 exhibit 高牛磺酸浓度,其转运体SLC6A6主要定位于LSPC(角膜缘干细胞、短暂扩增细胞和基底细胞),并呈年龄依赖表达模式。
- 抑制SLC6A6延迟角膜伤口愈合,触发衰老通路激活和多能性抑制,下调干性标志物(BCAM、p63、KRT14、Wnt4)和增殖标志物(Ki67),重现角膜衰老关键特征。
- 局部补充牛磺酸可逆转该功能衰退。
- VPA有效逆转GES的抑制效应,而DAPT减弱牛磺酸效应,表明Notch1信号通路参与牛磺酸诱导的LSPC维持。
关键数值与推荐
- 局部牛磺酸补充浓度为25 mg/mL,每日5次,用于老年小鼠角膜上皮刮除后。
- GES用于药理学抑制SLC6A6;VPA作为Notch1激动剂;DAPT(GSI-IX)作为Notch1抑制剂。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to elucidate the role of SLC6A6-mediated taurine transport in maintaining corneal limbal stem/progenitor cell (LSPC) function and its implications for age-associated corneal wound healing. METHODS: Corneal amino acid profiles from C57BL/6J mice were analyzed via liquid chromatography-tandem mass spectrometry (LC-MS/MS). SLC6A6 expression patterns were mapped using single-cell RNA sequencing, quantitative PCR, and immunofluorescence. Pharmacological inhibition of SLC6A6 with guanidinoethyl sulfonate (GES) was applied in corneal wound healing models and murine corneal epithelial stem/progenitor (TKE2) cells. Transcriptomic profiling, RNA/protein analyses, and functional assays were performed in GES-treated TKE2 cells. Aged mice with corneal epithelium scraping received topical taurine supplementation (25 mg/mL, 5 times/day), and the corneas were collected for immunofluorescence staining. Moreover, TKE2 cells were treated with GES along with the Notch1 agonist valproic acid (VPA), or they were treated with taurine along with the Notch1 inhibitor GSI-IX (DAPT). RESULTS: The cornea exhibited high taurine concentrations, with its transporter SLC6A6 predominantly localized in LSPCs (limbal stem cells, transient amplifying cells, and basal cells) and displaying age-dependent expression patterns. SLC6A6 inhibition delayed corneal wound healing, triggered senescence pathway activation and pluripotency suppression, and downregulated stemness markers (BCAM, p63, KRT14, Wnt4) and proliferative markers (Ki67), which recapitulated key features of corneal aging. This functional decline was reversed through topical taurine supplementation. Moreover, VPA effectively reversed the inhibitory effect of GES, whereas DAPT attenuated the effect of taurine, indicating involvement of the Notch1 signaling pathway in taurine-induced LSPC maintenance. CONCLUSIONS: SLC6A6-driven taurine uptake critically regulates LSPC homeostasis, presenting a therapeutic strategy for age-related corneal disorders.
引用
- Li Y, Xie F, Yang L, et al. SLC6A6-Mediated Taurine Uptake Sustains Corneal Epithelial Stem/Progenitor Cell Function to Counteract Age-Related Dysfunction. Invest Ophthalmol Vis Sci. 2025. PMID: 40478558. doi:10.1167/iovs.66.6.25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。